Danish Research Centre for Magnetic Resonance Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2009
NCT01144117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Danish Research Centre for Magnetic Resonance

Active Ingredients

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

tadalafil (cialis) (1 trial)

Drugs in Phase 1 Trials (1)

memantine (namenda) (1 trial)

Drugs in Other Trials (3)

epinephrine (levophed) (1 trial)

glucagon (1 trial)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6